Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Background: Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy. Objective: To better understand the frequency and management of sele...

Full description

Bibliographic Details
Main Authors: Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:European Urology Open Science
Subjects:
Erdafitinib
Fibroblast growth factor inhibitor
Toxicity
Urothelial carcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168323000137

Internet

http://www.sciencedirect.com/science/article/pii/S2666168323000137

Similar Items